Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease
Aim. To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual disease (MRD). Subjects and methods. In January...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2017-07-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32258/pdf |
id |
doaj-6bed35a2edcd43f2b8c1eed8fa6964d0 |
---|---|
record_format |
Article |
spelling |
doaj-6bed35a2edcd43f2b8c1eed8fa6964d02020-11-25T03:25:15Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422017-07-01897253110.17116/terarkh201789725-3129258Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual diseaseM V SolovyevL P MendeleevaO S PokrovskayaM V NareykoM V FirsovaI V GaltsevaYu O DavydovaN M KapranovL A KuzminaE G GemdzhianV G SavchenkoAim. To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual disease (MRD). Subjects and methods. In January 2014 to February 2016, fifty-two MM patients (19 men and 33 women) aged 24 to 66 years (median 54 years), who had achieved CR after auto-HSCT, were randomized to perform maintenance therapy with bortezomib during a year. On day 100 after auto-HSCT, all the patients underwent immunophenotyping of bone marrow plasma cells by 6-color flow cytometry to detect MRD. Relapse-free survival (RFS) was chosen as a criterion for evaluating the efficiency of maintenance therapy. Results. After auto-HSCT, MRD-negative patients had a statistically significantly higher 2-year RFS rate than MRD-positive patients: 52.9% (95% confidence interval (CI), 35.5 to 70.5%) versus 37.2% (95% CI, 25.4 to 49.3%) (p=0.05). The presence of MRD statistically significantly increased the risk of relapse (odds ratio 1.7; 95% CI, 1.2 to 3.4; p=0.05). Two-year cumulative risk of relapse (using the Kaplan-Meier) after auto-HSCT did not statistically significantly differ in MRD-negative patients receiving (n=15) and not receiving (n=10) maintenance therapy with bortezomib (p=0.58). After completion of maintenance treatment, 42% of the MRD-positive patients achieved a negative status. In the MRD-positive patients who had received maintenance therapy, the average time to recurrence was 5 months longer than that in the naïve patients: 17.3 versus 12.3 months. Conclusion. The MRD status determined in MM patients who have achieved CR after auto-HSCT is an important factor for deciding on the use of maintenance therapy.https://ter-arkhiv.ru/0040-3660/article/viewFile/32258/pdfmultiple myelomaminimal residual diseaseautologous hematopoietic stem cell transplantationmaintenance therapy |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
M V Solovyev L P Mendeleeva O S Pokrovskaya M V Nareyko M V Firsova I V Galtseva Yu O Davydova N M Kapranov L A Kuzmina E G Gemdzhian V G Savchenko |
spellingShingle |
M V Solovyev L P Mendeleeva O S Pokrovskaya M V Nareyko M V Firsova I V Galtseva Yu O Davydova N M Kapranov L A Kuzmina E G Gemdzhian V G Savchenko Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease Терапевтический архив multiple myeloma minimal residual disease autologous hematopoietic stem cell transplantation maintenance therapy |
author_facet |
M V Solovyev L P Mendeleeva O S Pokrovskaya M V Nareyko M V Firsova I V Galtseva Yu O Davydova N M Kapranov L A Kuzmina E G Gemdzhian V G Savchenko |
author_sort |
M V Solovyev |
title |
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
title_short |
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
title_full |
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
title_fullStr |
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
title_full_unstemmed |
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
title_sort |
multiple myeloma: maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2017-07-01 |
description |
Aim. To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual disease (MRD). Subjects and methods. In January 2014 to February 2016, fifty-two MM patients (19 men and 33 women) aged 24 to 66 years (median 54 years), who had achieved CR after auto-HSCT, were randomized to perform maintenance therapy with bortezomib during a year. On day 100 after auto-HSCT, all the patients underwent immunophenotyping of bone marrow plasma cells by 6-color flow cytometry to detect MRD. Relapse-free survival (RFS) was chosen as a criterion for evaluating the efficiency of maintenance therapy. Results. After auto-HSCT, MRD-negative patients had a statistically significantly higher 2-year RFS rate than MRD-positive patients: 52.9% (95% confidence interval (CI), 35.5 to 70.5%) versus 37.2% (95% CI, 25.4 to 49.3%) (p=0.05). The presence of MRD statistically significantly increased the risk of relapse (odds ratio 1.7; 95% CI, 1.2 to 3.4; p=0.05). Two-year cumulative risk of relapse (using the Kaplan-Meier) after auto-HSCT did not statistically significantly differ in MRD-negative patients receiving (n=15) and not receiving (n=10) maintenance therapy with bortezomib (p=0.58). After completion of maintenance treatment, 42% of the MRD-positive patients achieved a negative status. In the MRD-positive patients who had received maintenance therapy, the average time to recurrence was 5 months longer than that in the naïve patients: 17.3 versus 12.3 months. Conclusion. The MRD status determined in MM patients who have achieved CR after auto-HSCT is an important factor for deciding on the use of maintenance therapy. |
topic |
multiple myeloma minimal residual disease autologous hematopoietic stem cell transplantation maintenance therapy |
url |
https://ter-arkhiv.ru/0040-3660/article/viewFile/32258/pdf |
work_keys_str_mv |
AT mvsolovyev multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT lpmendeleeva multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT ospokrovskaya multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT mvnareyko multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT mvfirsova multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT ivgaltseva multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT yuodavydova multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT nmkapranov multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT lakuzmina multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT eggemdzhian multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease AT vgsavchenko multiplemyelomamaintenancetherapyafterautologoushematopoieticstemcelltransplantationdependingonminimalresidualdisease |
_version_ |
1724598019604611072 |